PolandPoland

European AIDS Conference: Biotechnology Fighting HIV Threat

23.11.2003

Warsaw - The Polish capital hosted the 9th European AIDS Conference (EACS) from October 25-29. As Europe is moving fast in the fight against HIV, approximately 3,000 visitors at this year's conference venue - the Warsaw International Expo-centre EXPO XXI (see photo) - affirmed the very high interest in this topic.
Among the latest results of retroviral therapy and the presentation of the 48 week in treatment-data of F. Hoffmann-La Roche's fusion inhibitor and potential block buster Fuzeon, modern biotechnological approaches were discussed thoroughly. Prof Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland, debated the pros and cons of HIV-vaccines. As companies like Merck, Aventis, GSK, Bavarian Nordic and Acambis are already developing vaccine candidates using different vectors and are conducting pre- and even clinical trials, this new approach in the fight against HIV still has to suffer many setbacks. Early this year the vaccine AIDSVAX by the U.S. company VaxGen Inc. flunked phase III trials. The future of the once promissing drug candidate is still uncertain.

PolandPoland

09.05.2011

Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross...

PolandPoland

06.04.2011

Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...

PolandPoland

04.04.2011

Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...

PolandPoland

25.02.2011

Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...

PolandPoland

06.02.2011

Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...

PolandPoland

04.11.2010

Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...

PolandPoland

19.09.2010

Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not...

PolandPoland

18.09.2010

Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...

PolandPoland

10.07.2010

Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...

PolandPoland

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/1/article/european-aids-conference-biotechnology-fighting-hiv-threat.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR33.6%
  • CO.DON3.14 EUR27.6%
  • FORMYCON8.20 EUR16.3%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.10 EUR-16.7%
  • MOLOGEN6.60 EUR-12.8%

TOP

  • SANTHERA86.95 CHF2146.8%
  • PAION3.22 EUR238.9%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.3%
  • MOLOGEN6.60 EUR-44.5%
  • 4SC1.04 EUR-44.4%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products